TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03182556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electromyography-Biofeedback (EMG-BFB) training
Description: The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Electromyography-Biofeedback (EMG-BFB) training
Description: The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aquatic exercise
Description: Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
Study: NCT00921505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Tablets (2 x 600 mg) oral single dose (2 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 1000 mg
Description: Tablets (2 x 500 mg) oral single dose (2 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol + ibuprofen
Description: Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
Study: NCT00428727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled nitric oxide releasing patch
Description: daily application of nitric oxide patch during 90 days
Study: NCT02923778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT or via intralesional injection
Study: NCT02722096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axillary block anesthesia with Ropivacaine and Lidocaine
Description: Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
Study: NCT00428727

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: daily application during 90 days
Study: NCT02369835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dakin's solution
Description: Apply modified Dakin's solution (0.005 to 0.01%) topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied topically
Study: NCT01827540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Study: NCT03747757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Undergo CBT
Study: NCT01827540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Study: NCT02722096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with Ropivacaine and Lidocaine
Description: Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
Study: NCT03565965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.
Study: NCT04705038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
Study: NCT03636711

Intervention type: OTHER
Intervention: antibiotic protocol, according to a syndromic approach
Description: Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
Study: NCT00300118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 9 mg
Study: NCT01827540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Study: NCT03747757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02113813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: oral
Study: NCT01827540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT04656028

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database \<0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
Study: NCT02820610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
Study: NCT05186077

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired

Intervention type: OTHER
Intervention: Psychiatric testing
Description: Subjects will be evaluated using psychiatric assessments

Intervention type: OTHER
Intervention: Psychiatric testing
Description: Subjects will be evaluated using psychiatric assessments

Intervention type: OTHER
Intervention: Eye-Tracking
Description: Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.

Intervention type: OTHER
Intervention: Eye-Tracking
Description: Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.

Intervention type: OTHER
Intervention: Neuropsychology Evaluation
Description: The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function

Intervention type: OTHER
Intervention: Neuropsychology Evaluation
Description: The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
Study: NCT01861275

Intervention type: DEVICE
Intervention: Nasal CPAP
Description: Nasal CPAP treatment for obstructive sleep apnoea
Study: NCT03233971

Intervention type: OTHER
Intervention: rPATD Questionnaire
Description: A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.

Intervention type: OTHER
Intervention: rPATD Questionnaire
Description: A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
Study: NCT00300118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalazine
Description: 4.5 g
Study: NCT02184884

Intervention type: DEVICE
Intervention: MACE after OPCAB

Intervention type: DEVICE
Intervention: without MACE after OPCAB
Study: NCT02366585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin gel applied to two periodontal pockets
Study: NCT02025348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IntelliCap
Description: Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IntelliCap
Description: Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IntelliCap
Description: Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IntelliCap
Description: Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
Study: NCT01164163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib phosphate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT04889781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Compare the effect of dexamethasone injection on reducing post-op pain after impacted third molar Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Compare the effect of dexamethasone injection on reducing post-op pain after impacted third molar Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Compare the effect of Piezosurgery device use on reducing post-op pain after impacted third molar Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Compare the effect of Piezosurgery device use on reducing post-op pain after impacted third molar Surgery
Study: NCT02820610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9 %
Description: 2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
Study: NCT04545112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CABG
Description: Elective, on-pump coronary artery bypass (CABG) surgery. Each study subject will receive an internal mammary artery (IMA) conduit to the left anterior descending (LAD) coronary artery, one saphenous vein graft and one XABG medical device.
Study: NCT01969175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load and milk-free diet
Study: NCT01379443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTN model of care for children and their families
Description: Parental reports on the quality of life of their children and service needs
Study: NCT03252639

Intervention type: PROCEDURE
Intervention: EVT for RAS & PBV acquisition protocol for target kidneys
Study: NCT02662686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfer according to morphological criteria
Description: Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer according to the MitoScore results
Description: Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
Study: NCT04624893

Intervention type: DRUG
Intervention: Polatuzumab Vedotin-Piiq
Description: Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
Study: NCT01432314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop.
Study: NCT00235729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an exact match of lofexidine, less the active ingredient.
Study: NCT02695485

Intervention type: PROCEDURE
Group type: OTHER
Intervention: innervated sensate flap
Description: sensory reconstruction via digital nerve repair with the donor nerve of the flap
Study: NCT02158858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT02983981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topicort Topical Spray
Description: open label Topicort spray
Study: NCT02897193

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICE dental implant 4.2 mm
Description: ICE dental implant 4.2 mm diameter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICE dental implant 3.2 mm
Description: NICE dental implant 4.2 mm diameter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Bio's Graft Bovine bone
Description: Alpha Bio's Graft Bovine Bone
Study: NCT03734744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
Study: NCT02517970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology distraction
Description: Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
Study: NCT04163822

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, only observation

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, only observation
Study: NCT04991428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.